Hiperparatiroidismo primario

Gutiérrez Díaz Ceballos, María Esther; Rodríguez Martínez, Héctor A; Torres Acosta, Evelyn M; Cruz Ortiz, Humberto.
Rev. Fac. Med. UNAM ; 44(1): 32-34, ene.-feb. 2001. ilus, CD-ROM
Artículo en Español | LILACS | ID: lil-314355

Documentos relacionados

  1. An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant.
  2. Atypical Multiple Myeloma Case: Atypical Clinical Presentation, in Female and at Young Age.
  3. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
  4. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
  5. Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
  6. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant.
  7. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
  8. Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.
  9. Refractory multiple myeloma: Count refractory drugs, not lines of treatment!
  10. Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.